TACE Combined With Sintilimab Plus Bevacizumab Biosimilar in Patients With Advanced Hepatocellular Carcinoma (TASK-02)
Status:
Recruiting
Trial end date:
2024-07-15
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the efficacy and safety of TACE combined with
Sintilimab plus bevacizumab biosimilar in patients with advanced hepatocellular carcinoma as
first-line therapy.